Key takeaway: On August 14, 2026, Alkem Laboratories Limited reported an 11% revenue growth for Q1FY27, with total revenue from operations reaching ₹37,402 million, reflecting a year-on-year increase of 10.9%. The domestic sales contributed ₹24,978 million, growing by 10.3%, while international sales rose by 16.0% to ₹12,223 million. EBITDA was reported at ₹7,661 million, with a margin of 20.5%, up 3.7% year-on-year. However, net profit after non-controlling interest decreased by 21.7% to ₹5,200 million. Management highlighted strong growth in non-US international markets and emphasized the need for improvement in execution and operational consistency. The company is investing in R&D, MedTech, and Biotech to support future growth. The earnings call was scheduled for the same day to discuss these results further.

Key takeaway: The Q4 FY2026 Earnings Conference Call for Alkem Laboratories Limited, held on May 28, 2026, featured management discussing a landmark year with record profitability, surpassing INR3,000 crores in EBITDA. Management highlighted strong growth in both domestic and international markets, particularly in chronic therapies and new product launches, including semaglutide. Q4 total revenue reached INR36,033 million, with a year-on-year growth of 14.6%. The company reported an EBITDA margin of 14.4% for Q4 FY2026. Management acknowledged potential near-term headwinds due to geopolitical factors and rising logistics costs but expressed confidence in their ability to manage supply chain disruptions. The discussion also covered strategic priorities, capital allocation, and the ongoing transition in leadership, with Dr. Vikas Gupta departing the company. The call concluded with management inviting questions from analysts and investors.

Key takeaway: On May 28, 2026, Alkem Laboratories Ltd. announced its financial results for Q4FY26 and FY26, highlighting record high EBITDA and strong revenue growth. The presentation reported total revenue from operations of ₹36,033 million for Q4FY26, marking a 14.6% year-over-year increase, with domestic sales growing by 8.8% and international sales by 25.4%. EBITDA reached ₹5,174 million, a 32.2% increase from the previous year, resulting in an EBITDA margin of 14.4%. For FY26, total revenue was ₹147,123 million, up 13.5% year-over-year, with net profit after non-controlling interest at ₹23,018 million, reflecting a 6.3% increase. Management noted strong performance in both domestic and international markets, with significant contributions from chronic therapies and a robust launch pipeline. The company also reported a positive outperformance against the Indian Pharmaceutical Market in key segments.

Key takeaway: On February 18, 2026, Alkem Laboratories Limited submitted an updated investor presentation regarding Alkem MedTech’s strategic direction. The presentation highlighted the global MedTech market's growth potential, projected to reach $870 billion by 2030, and emphasized Alkem MedTech's focus on orthopedic and cardiovascular segments. Management reported on the company's journey in the musculoskeletal market, including plans for product launches and a goal of achieving significant market share in India by the fifth year. Additionally, the presentation detailed the acquisition of a majority stake in Occlutech Holding AG, aimed at enhancing Alkem's cardiovascular portfolio. The document outlined the strategic rationale for the acquisition, including synergies and operational efficiencies. Management noted that the acquisition would be funded through internal accruals and is subject to regulatory approvals, with completion anticipated by June 2026.

Key takeaway: On February 16, 2026, Alkem Laboratories Limited submitted an investor presentation regarding Alkem MedTech’s strategic direction for an upcoming investor meet scheduled for February 18, 2026. The presentation highlighted the global MedTech market's growth potential, projected to reach $870 billion by 2030, and emphasized Alkem MedTech's focus on orthopedic and cardiovascular segments. Management reported on the company's progress in the musculoskeletal area, including CE approvals for knee and hip products and a goal of achieving significant market share in India within five years. Additionally, the presentation detailed the acquisition of a 51-55% stake in Occlutech Holding AG, aimed at enhancing Alkem's global cardiovascular strategy. The acquisition is set to be funded through internal accruals and is subject to regulatory approvals, anticipated to be completed by June 2026.

Key takeaway: On February 13, 2026, Alkem Laboratories Limited reported an 11% revenue growth for Q3 FY26, with total revenue from operations reaching ₹37,368 million. The company announced a binding term sheet to acquire a majority stake in Occlutech Holding AG, a global medical devices company, which management described as strategically important for expanding into the medical devices sector. CEO Dr. Vikas Gupta highlighted stable performance in a dynamic environment, with domestic sales of ₹24,959 million growing by 5.5% year-over-year, while international sales surged by 26.6% to ₹12,157 million. The earnings before interest, tax, depreciation, and amortization (EBITDA) was ₹8,280 million, reflecting a margin of 22.2%. Net profit after non-controlling interest was reported at ₹6,360 million, a 1.6% increase year-over-year. The company also noted its growth in key therapy areas, outperforming the Indian Pharmaceutical Market in several segments.